- Business Wire•9 hours ago
AVEO Oncology today announced that its pivotal, Phase 3 TIVO-3 trial, a randomized, controlled, multi-center, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma , has successfully completed the first safety review by the study’s Safety Monitoring Committee .
- Business Wire•14 days ago
AVEO Oncology today announced clinical and regulatory updates for its lead drug candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor tyrosine kinase inhibitor .
- Business Wire•17 days ago
AVEO Oncology today announced that Michael Needle, M.D., Chief Medical Officer, will present at the 19th Annual BIO CEO & Investor Conference on Monday, February 13, 2017 at 8:30 AM E.T.
AVEO : Summary for AVEO Pharmaceuticals, Inc. - Yahoo Finance
AVEO Pharmaceuticals, Inc. (AVEO)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||0.80 x 1000|
|Ask||0.81 x 5300|
|Day's Range||0.78 - 0.88|
|52 Week Range||0.54 - 1.23|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-1.88|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|